Ignite Creation Date:
2024-05-06 @ 7:40 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06096025
Status:
RECRUITING
Last Update Posted:
2023-11-18
First Post:
2023-10-17
Brief Title:
Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections
Sponsor:
Methodist Health System
Organization:
Methodist Health System
Study Overview
Official Title:
Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Streptococcus pneumoniae is a gram-positive GP bacteria responsible for common infections such as community-acquired pneumonia CAP as well as complicated infections such as bacteremia infective endocarditis and meningitis S pneumoniae bacteremia ranks among the top 10 most common pathogens associated with bloodstream infections and correlates with high morbidity and mortality worldwide
Detailed Description:
The Infectious Diseases Society of America IDSA guidelines for CAP management advocate for short courses of antibiotics for CAP treatment However it does not address duration of therapy for common CAP pathogens such as S pneumoniae when associated with blood stream infections BSI 3
Currently GP bacteremia duration of therapy typically ranges from 7 to 14 days based on IDSA guideline recommendations for Staphylococcus aureus bacteremia with no further definitive consensus4 Additionally lack of data and randomized clinical trials on the efficacy and safety of short compared to long treatment duration have led to variability in practice Most randomized clinical trials as well as retrospective studies on treatment duration have been conducted mainly in gram-negative BSI
Currently GP bacteremia duration of therapy typically ranges from 7 to 14 days based on IDSA guideline recommendations for Staphylococcus aureus bacteremia with no further definitive consensus4 Additionally lack of data and randomized clinical trials on the efficacy and safety of short compared to long treatment duration have led to variability in practice Most randomized clinical trials as well as retrospective studies on treatment duration have been conducted mainly in gram-negative BSI
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None